Janssen Biotech Inc announced that the U.S. FDA has approved STELARA® (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.
captcha